Lupin receives USFDA approval for Oral Contraceptive Vyfemla tablets

28 Sep 2013 Evaluate

Lupin has received final approval for its Vyfemla tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 0.4mg/0.035 mg) from the United States Food and Drugs Administration (USFDA) to market a generic version of Warner Chilcott Company, LLC.’s Ovcon 35 Tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 0.4mg/0.035 mg). Lupin’s US subsidiary Lupin Pharmaceuticals Inc (LPI) shall commence marketing the product shortly.

Lupin's Vyfemla Tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 0.4 mg/0.035 mg) is the AB rated generic equivalent of Warner Chilcott's Ovcon 35 Tablets and is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Warner Chilcott Company, LLC’s Ovcon 35 Tablets had annual U.S sales of approximately US$ 22.3 million (IMS MAT Mar 2013).

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

Lupin Share Price

2087.85 -24.15 (-1.14%)
01-Jan-2026 11:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1711.25
Dr. Reddys Lab 1254.10
Cipla 1503.00
Zydus Lifesciences 911.20
Lupin 2087.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×